Aegis now an Anthem Blue Cross and Blue Shield of Georgia participating provider

NASHVILLE, TN (June 17, 2019) - Aegis Sciences Corporation is pleased to announce that effective June 17, 2019 we will be a participating laboratory provider…

NASHVILLE, TN (June 17, 2019) - Aegis Sciences Corporation is pleased to announce that effective June 17, 2019 we will be a participating laboratory provider with Anthem Blue Cross and Blue Shield in Georgia for PPO, Medicare Advantage and Indemnity products. Our product participation with Anthem Blue Cross and Blue Shield in Georgia will allow referring physicians to utilize Aegis’ laboratory services…

New Research Shows How Diagnostic Testing Can Advance the Identification and Treatment of Harmful Drug-Drug Interactions

Findings of a recently published two-part study demonstrate that InterACT Rx™ can significantly enhance diagnosis and treatment of DDIs, improving patient…

Findings of a recently published two-part study demonstrate that InterACT Rx™ can significantly enhance diagnosis and treatment of DDIs, improving patient outcomes NASHVILLE, TN (December 5, 2018) - Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative testing and consulting services to providers, conducted a two-part research study to measure the performance…

New Research Reveals the Prevalence of Drug-Drug Interactions and the Economic Impact on the Healthcare System

Studies show an alarming prevalence of concurrent ingestion of interacting substances by patients and that providing physicians with clear, objective information…

Studies show an alarming prevalence of concurrent ingestion of interacting substances by patients and that providing physicians with clear, objective information leads to a reduction of interactions and costs for patients NASHVILLE, TN (November 5, 2018) – Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative testing and consulting services to providers, recently…

Aegis now offering definitive testing for kratom

Nashville, Tennessee (Nov. 5, 2018) - Aegis Sciences Corporation is pleased to announce definitive testing for kratom (mitragynine) via liquid chromatography-…

Nashville, Tennessee (Nov. 5, 2018) - Aegis Sciences Corporation is pleased to announce definitive testing for kratom (mitragynine) via liquid chromatography- tandem mass spectrometry (LC-MS/MS). Kratom, botanically known as Mitragyna speciosa, refers to a tropical tree found in parts of Southeast Asia belonging to the Rubiaceae family.1,2 The leaves of this tree have traditionally been used as an…

Aegis Study Shows Impact of InterACT Rx on Medication Management and Patient Care

Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider’s insights, drive clinical decision…

Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider’s insights, drive clinical decision making, and improve patient outcomes. Nashville, Tennessee (Oct. 9, 2018) - In a recently published study of 262 patients, there was a signifcant reduction in all-cause and painrelated outpatient visits and medication use between the pre- and…

Aegis study reports prevalence of identified drug-drug interactions based on detection of ingested substances.

InterACT Rx™ identified at least one drug-drug interaction (DDI) between recently ingested substances in as many as 20% of patients. Nashville, Tennessee…

InterACT Rx™ identified at least one drug-drug interaction (DDI) between recently ingested substances in as many as 20% of patients. Nashville, Tennessee (Sept. 19, 2018) - In a recently published study of more than 15,000 patients, 20% had at least one DDI identified. Risk of DDIs has been shown to contribute to patient harm, hospitalization, and increased healthcare costs. Despite improvements in…

Aegis Sciences Launches New Medication Adherence Tool for Behavioral Healthcare

AcuRiseID™ is a new urinalysis that monitors medication adherence in people with mental illness and substance abuse disorder Nashville, Tennessee (Sept.…

AcuRiseID™ is a new urinalysis that monitors medication adherence in people with mental illness and substance abuse disorder Nashville, Tennessee (Sept. 12, 2018) – Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative testing and consulting services to providers, today launched AcuRiseID™, a new tool that offers accurate and informative medication monitoring…

Kara Allen named Fellow of the American Chemical Society

Nashville, Tenn. (August 3, 2018) – Kara Allen, Aegis Sciences Corporation’s Director, Recruitment and University Relations, has been named a fellow of…

Nashville, Tenn. (August 3, 2018) – Kara Allen, Aegis Sciences Corporation’s Director, Recruitment and University Relations, has been named a fellow of the American Chemical Society (ACS). She is among 51 new fellows named to the 2018 class. “I am honored and very humbled to be recognized alongside such an amazing group of chemists, many of whom I have collaborated with and admired for a number of…

Aegis Sciences Corporation announces laboratory expansion open house

Nashville, TN – July 24, 2018 - Aegis Sciences Corporation, a national leader in healthcare and forensic laboratory sciences, is expanding! Wednesday,…

Nashville, TN – July 24, 2018 - Aegis Sciences Corporation, a national leader in healthcare and forensic laboratory sciences, is expanding! Wednesday, August 1st, 2018501 Great Circle Road (parking behind building)6:00 p.m. to 8:00 p.m. Meet with our recruiters and laboratory leaders to learn about our recent growth, exciting new opportunities, and competitive benefits package. We are seeking new…

Aegis Sciences Rebrands Drug Interaction Test to InterACT Rx

InterACT RxTM testing detects over 120 substances known to cause adverse drug interactions.Nashville, Tenn. (July 12, 2018) – Aegis Sciences Corporation,…

InterACT RxTM testing detects over 120 substances known to cause adverse drug interactions.Nashville, Tenn. (July 12, 2018) – Aegis Sciences Corporation, a leading healthcare company that provides information to clinicians to help them make better decisions through medication adherence testing, is pleased to announce InterACT RxTM as the name for its Drug-Drug Interaction (DDI) testing. “The new name…